|
Neonatal diabetes mellitus
|
0.310 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
We identified homozygous mutations in 7 different genes in 11 unrelated patients and show that NKX2-2 and MNX1 are etiological genes for neonatal diabetes, thus confirming their key role in development of the human pancreas.
|
24411943 |
2014 |
|
Neonatal diabetes mellitus
|
0.310 |
Biomarker
|
disease |
BEFREE |
We identified homozygous mutations in 7 different genes in 11 unrelated patients and show that NKX2-2 and MNX1 are etiological genes for neonatal diabetes, thus confirming their key role in development of the human pancreas.
|
24411943 |
2014 |
|
Neonatal diabetes mellitus
|
0.310 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
|
|
|
|
Demyelinating Diseases
|
0.200 |
Biomarker
|
group |
RGD |
Transient upregulation of Nkx2.2 expression in oligodendrocyte lineage cells during remyelination.
|
15048854 |
2004 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Mechanistically, we revealed that NKX2-2 acts as a tumor suppressor partially by mediating the transcriptional downregulation of COL5A2, PLAU, SEMA7A and S1PR1 genes.
|
30210629 |
2018 |
|
Sarcoma
|
0.040 |
AlteredExpression
|
group |
BEFREE |
One EWSR1-NFATC2 sarcoma co-expressed PAX7 and NKX2-2.
|
29920735 |
2018 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
NKX2-2 was positive in 9 (75%) mesenchymal chondrosarcomas, 8 (80%) olfactory neuroblastomas, 1 CIC-DUX4 sarcoma, 1 poorly differentiated synovial sarcoma, 1 neuroblastoma, 2 unclassified round cell sarcomas, and 3 small cell carcinomas; all other EWSR1-associated tumors were negative for NKX2-2, apart from 1 desmoplastic small round cell tumor, 1 myoepithelioma, and 1 myoepithelial carcinoma.
|
26847175 |
2016 |
|
Sarcoma
|
0.040 |
Biomarker
|
group |
BEFREE |
Nonetheless, NKX2-2 may be helpful to distinguish Ewing sarcoma from some histologic mimics including CIC-DUX4 and BCOR-CCNB3 sarcomas.
|
26847175 |
2016 |
|
Sarcoma
|
0.040 |
AlteredExpression
|
group |
LHGDN |
EWS/FLI mediates transcriptional repression via NKX2.2 during oncogenic transformation in Ewing's sarcoma.
|
18414662 |
2008 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Five of 10 genes (i.e., six-transmembrane epithelial antigen of the prostate 1 [STEAP1], cyclin D1 [CCND1], NKX2-2 transcription factor [NKX2-2], plakophilin 1 [PKP1], and transmembrane protein 47 [TMEM47]) were chosen for further analyses based on their steep linear dynamic range in detecting tumor cells seeded in normal mononuclear cells and on their homogeneous expression among EFT tumors.
|
18056173 |
2007 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
In addition to GFAP, therefore, YKL-40, ApoE, ASCL1, and NKX2-2 represent promising tumor cell markers to distinguish oligodendrogliomas from astrocytomas.
|
17146289 |
2006 |
|
Sarcoma
|
0.040 |
Biomarker
|
group |
LHGDN |
Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma.
|
16697960 |
2006 |
|
Neoplasm Metastasis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
In summary, our studies of NKX2-2 revealed new molecular mechanisms underlying osteosarcoma proliferation and metastasis and may provide a series of potential therapeutic targets for osteosarcoma.
|
30210629 |
2018 |
|
Ewings sarcoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
The 20p11.22 locus is near NKX2-2, a highly overexpressed gene in EWS.
|
30093639 |
2018 |
|
Malignant neoplasm of soft tissue
|
0.020 |
AlteredExpression
|
group |
BEFREE |
One EWSR1-NFATC2 sarcoma co-expressed PAX7 and NKX2-2.
|
29920735 |
2018 |
|
Ewings sarcoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Nonetheless, NKX2-2 may be helpful to distinguish Ewing sarcoma from some histologic mimics including CIC-DUX4 and BCOR-CCNB3 sarcomas.
|
26847175 |
2016 |
|
Malignant neoplasm of soft tissue
|
0.020 |
Biomarker
|
group |
BEFREE |
Nonetheless, NKX2-2 may be helpful to distinguish Ewing sarcoma from some histologic mimics including CIC-DUX4 and BCOR-CCNB3 sarcomas.
|
26847175 |
2016 |
|
Neoplasm Metastasis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Marker negativity of STEAP1, CCND1, or NKX2-2, as well as three markers in combination, was strongly correlated with patient survival as well as survival without new metastases.
|
18056173 |
2007 |
|
Hodgkin Disease
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
NKL homeobox gene NKX2-2 is aberrantly expressed in Hodgkin lymphoma.
|
30680064 |
2018 |
|
Osteosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In summary, our studies of NKX2-2 revealed new molecular mechanisms underlying osteosarcoma proliferation and metastasis and may provide a series of potential therapeutic targets for osteosarcoma.
|
30210629 |
2018 |
|
Adult Hodgkin Lymphoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
NKL homeobox gene NKX2-2 is aberrantly expressed in Hodgkin lymphoma.
|
30680064 |
2018 |
|
Childhood Hodgkin Lymphoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
NKL homeobox gene NKX2-2 is aberrantly expressed in Hodgkin lymphoma.
|
30680064 |
2018 |
|
Osteosarcoma of bone
|
0.010 |
Biomarker
|
disease |
BEFREE |
In summary, our studies of NKX2-2 revealed new molecular mechanisms underlying osteosarcoma proliferation and metastasis and may provide a series of potential therapeutic targets for osteosarcoma.
|
30210629 |
2018 |
|
Childhood Osteosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In summary, our studies of NKX2-2 revealed new molecular mechanisms underlying osteosarcoma proliferation and metastasis and may provide a series of potential therapeutic targets for osteosarcoma.
|
30210629 |
2018 |
|
Classical Hodgkin's Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, our data reveal ectopic activation of a neural gene network in HL placing NKX2-2 at its hub, highlighting a novel oncogenic impact of NKL homeobox genes in B-cell malignancies.
|
30680064 |
2018 |